Surgically ligating the left atrial appendage (LAA) during implantation of the HeartMate 3 left ventricular assist device (LVAD; Abbott) does not affect survival or hemocompatibility-related adverse ...

Pharmacotherapy for advanced heart failure patients with a HeartMate 3 left ventricular assist device (LVAD) is being simplified following US Food and Drug Administration approval of a labeling change ...

Please provide your email address to receive an email when new articles are posted on . “Less is more” when it comes to antithrombotic therapy for patients with the HeartMate 3 left ventricular assist ...

The majority of patients with an older left ventricular assist device (LVAD) as destination therapy did not exhibit cognitive decline over time, despite a high frequency of strokes, researchers found.

FDA has granted Thoratec Corp. permission to enlarge its pivotal trial for the next-generation HeartMate III left ventricular assist system (LVAS). This gives the company the ability to enroll a ...

Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today announced that it received final ...

Too old and too sick for a heart transplant, Arvid Herrman was given a choice: Have a mechanical pump implanted in his heart, potentially keeping him alive for several years, or do nothing and almost ...